1462
The Hirsch Pharmacy is opened in Frankfurt am Main, Germany. The Fresenius family assumes ownership in the 18th century.
History
1912
The pharmacist and proprietor of the Hirsch Pharmacy, Dr. Eduard Fresenius, founds the pharmaceutical company Dr. E. Fresenius. Its main products are pharmaceutical specialties such as injection solutions, serologic reagents and Bormelin nasal ointment.
1933/34
The manufacturing company is separated from the Hirsch Pharmacy and moves to Bad Homburg. Dr. Fresenius devotes more and more time to the company, which grows to around 400 employees.
1966
Fresenius starts to sell dialysis machines and dialyzer manufactured various foreign companies and gains substantial market shares.
1974
Fresenius starts to manufacture infusion solutions and medical disposables in St. Wendel, Saarland.
1979
The first ready-to use tube feed Fresubin® is introduced.
1984
Establishment of the home care concept by which patients who have to be fed enterally (intake of nutrients involving the gastro-intestinal tract) can be cared for at home. At the same time expansion of the enteral nutrition range.
1988
The within Fresenius developed Aminomix® Two-Chamber-Bag for parenteral nutrition is launched.
1993
Launch of Supportan®, a tube feed for enteral nutrition in oncology.
1995
Laying of the cornerstone of the innovative infusion solution plant in Friedberg (Hesse).
1997
Introduction of the world’s first dipeptide solution for parenteral nutrition. Inauguration of the state-of-the-art infusions solutions plant (Friedberg, Hesse), the most modern one in Europe.
1998
In December 1998 Fresenius acquired the international infusion business of Pharmcia & Upjohn (Kabi).
1999
Fresenius Kabi is formed by combining Fresenius Group's Pharma division with the international clinical nutrition business acquired from Pharmacia & Upjohn (Kabi). The new company is Europe's leader in the field of nutrition and infusion therapy, offering a comprehensive product and service portfolio worldwide for hospitals and patients at home.
Launch of a new generation of hydroxyethyl starch for volume therapy.
2000
Fresenius Kabi accelerates its worldwide business expansion by opening up new growth markets in Asia, Africa and Latin America.
2003
The business segment Fresenius HemoCare is reallocated within the Fresenius Group. Due to their similar technology platform, the Infusion Technology and Transfusion Technology Divisions are combined under one management and assigned to Fresenius Kabi.
2004
Fresenius Kabi strengthens its market positions with acquisitions in South Africa and Czech Republic as well as with a joint venture in Australia.
2005
Expansion of I.V. drug portfolio via acquisition of the Portuguese pharmaceutical company Labesfal.
Fresenius Kabi strengthens product portfolio and production network of medical devices through the acquisition of the business of Clinico.
2006
Acquisition of Argentinean pharmaceutical company Filaxis: Expansion of I.V. drug portfolio.
2007
Fresenius Kabi strengthens business activities through acquisitions.
Blood volume replacement: Acquisition of blood volume replacement business of Japanese pharmaceutical company Kyorin
I.V. Drugs: Acquisition of the Chilean company Laboratorio Sanderson and the Italian company Ribbon
Clinical Nutrition: Acquisition of the enteral nutrition businesses from Nestlé in France and Spain.
2008
Fresenius Kabi grows its I.V. generics business and expands into oncology drugs with the Dabur Pharma acquisition.
Fresenius Kabi enters the North American pharmaceuticals market and becomes a globally leading supplier in the field of intravenously administered generic drugs via the acquisition of the U.S. based APP Pharmaceuticals.
2012
Fresenius Kabi acquires the transfusion technology company Fenwal and creates a global leader in transfusion technology with a broad product portfolio for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
2014
Fresenius Kabi has over 32,000 employees and markets more than 100 different product groups in over 160 countries and continues to expand its product range and global presence.
2016
Fresenius Kabi expands its portfolio to ready-to-administer prefilled syringes by acquiring the U.S. BD Rx business from Becton Dickinson.
2017
Fresenius Kabi enters the growing biosimilars sector by acquiring an R&D pipeline with a focus on autoimmune diseases and oncology.
